27 completed. 27 Phase 1, 12 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 27 | Completed 27 |
| Phase 2 | 12 | Completed 12 |
Follow Nut and Peanut Hypersensitivity: new trials by email Literature Review of Nut and Peanut Hypersensitivity trials Research Report on Nut and Peanut Hypersensitivity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PK/PD Study of IN-001 Sublingual Spray in Healthy Adults Epinephrine Auto-Injector 0.3 mg/0.3 mL, Epinephrine 0.3 mg intramuscular manual injection via a syringe and needle, IN-001 9.06 mg Sublingual Spray - Food Allergy, Anaphylaxis | Phase 1 | Completed | Insignis Therapeutics, Inc. | 32 | 2025-10-24 | 2026-05-05 |
| Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IGNX001 IGNX001, Placebo - Peanut Allergy | Phase 1 | Completed | IgGenix Australia Pty Ltd | 32 | 2024-09-01 | 2025-11-14 |
| Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy Peanut SLIT-tablet, Placebo - Peanut Allergy | Phase 1 / Phase 2 | Completed | ALK-Abelló A/S | 209 | 2022-09-07 | 2026-05-11 |
| Pinpoint Trial: Prebiotics IN Peanut Oral ImmunoTherapy Prebiotic, Placebo - Peanut Allergy | Phase 1 / Phase 2 | Completed | University of Chicago | 20 | 2021-11-30 | 2026-03-09 |
| OMEGA Study: A Study of the Safety and Feasibility of Up-titration With INT301 in Adults With Sensitivity to Peanut INT301, Placebo - Peanut Allergy | Phase 1 | Completed | Intrommune Therapeutics | 32 | 2021-05-15 | 2023-07-28 |
| ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults Low dose ADP101, High dose ADP101, Pooled Placebo - Food Allergy | Phase 1 / Phase 2 | Completed | Alladapt Immunotherapeutics, Inc. | 73 | 2021-04-20 | 2024-05-16 |
| Boiled Peanut Oral Immunotherapy Boiled Peanut Powder - Peanut Hypersensitivity | Phase 1 | Completed | Alton Melton | 8 | 2019-11-05 | 2024-09-19 |
| A Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine ASP0892, Placebo - Peanut Allergy | Phase 1 | Completed | Astellas Pharma Global Development, Inc. | 20 | 2019-03-12 | 2024-10-23 |
| Salvage Peanut Oral Immunotherapy Study Peanut OIT - Peanut Allergy | Phase 1 / Phase 2 | Completed | University of North Carolina, Chapel Hill | 15 | 2018-01-03 | 2023-01-30 |
| A Study to Assess the Biological Potency of Peanut Allergen Extract in Adolescent and Adult Peanut Allergic Subjects DBV712 IHRP - Peanut Allergy | Phase 1 | Completed | DBV Technologies | 27 | 2017-11-24 | 2019-07-26 |
| Evaluating the Safety and Efficacy of Oral Encapsulated Fecal Microbiota Transplant in Peanut Allergic Patients Fecal Microbiota Capsule - Peanut Allergy | Phase 1 | Completed | Rima Rachid | 15 | 2017-03-03 | 2026-10-08 |
| A Study to Evaluate Safety, Tolerability and Immune Response in Adults Allergic to Peanut After Receiving Intradermal or Intramuscular Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine ASP0892 Intradermal, ASP0892 Intramuscular, Placebo Intradermal - Peanut Allergy | Phase 1 | Completed | Astellas Pharma Global Development, Inc. | 31 | 2016-12-13 | 2024-10-23 |
| HAL-MPE1 Safety and Tolerability Study HAL-MPE1, HAL-MPE1 placebo - Peanut Allergy | Phase 1 | Completed | HAL Allergy | 42 | 2016-12-01 | 2020-02-19 |
| Peanut Oral Immunotherapy in Children With Peanut Allergy (Peanut Flour) Peanut Oral Immunotherapy (POIT) - Peanut Allergic Subjects | Phase 1 | Completed | Baylor College of Medicine | 15 | 2014-07-31 | 2024-01-19 |
| HAL-MPE1 First-in-human HAL-MPE1, Placebo - Peanut Allergy | Phase 1 | Completed | HAL Allergy | 17 | 2014-06-01 | 2015-07-10 |
| Tolerance Following Peanut Oral Immunotherapy Peanut Flour, Oat Flour - Peanut Allergy | Phase 1 / Phase 2 | Completed | Massachusetts General Hospital | 41 | 2013-08-01 | 2021-07-28 |
| Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial Omalizumab, placebo - Peanut Allergy, Food Allergy | Phase 1 / Phase 2 | Completed | Boston Children's Hospital | 36 | 2013-01-01 | 2023-02-21 |
| Walnut Oral Immunotherapy for Tree Nut Allergy Walnut Protein Powder, Oat Powder (placebo), Open-label Walnut Protein Powder - Tree Nut Allergy | Phase 1 / Phase 2 | Completed | University of Arkansas | 22 | 2012-04-27 | 2023-05-12 |
| Sublingual Immunotherapy for Peanut Allergy and Induction of Tolerance Liquid peanut extract (Peanut SLIT) - Peanut Hypersensitivity, Food Hypersensitivity | Phase 1 / Phase 2 | Completed | University of North Carolina, Chapel Hill | 54 | 2011-06-01 | 2019-06-12 |
| Xolair Enhances Oral Desensitization in Peanut Allergic Patients Omalizumab - Peanut Allergy | Phase 1 / Phase 2 | Completed | Lynda Schneider | 13 | 2011-02-01 | 2015-04-07 |
Showing 20 of 27. Sign in to see all of them.
Peanut Hypersensitivity (26) · Food Hypersensitivity (15) · Hypersensitivity (8) · Hypersensitivity, Immediate (5) · Anaphylaxis (4) · Nut Hypersensitivity (3) · Egg Hypersensitivity (1) · Immune System Diseases (1) · Milk Hypersensitivity (1) · Shellfish Hypersensitivity (1) · Wheat Hypersensitivity (1)
Immune System Diseases (26) · Hypersensitivity, Immediate (22) · Hypersensitivity (19) · Food Hypersensitivity (12)
Omalizumab (3) · Epinephrine (1) · Fecal Microbiota Transplantation (1) · Glycerol (1) · Immunotherapy (1) · Needles (1) · Prebiotics (1)
University of North Carolina, Chapel Hill (3) · Astellas Pharma Global Development, Inc. (2) · DBV Technologies (2) · HAL Allergy (2) · ALK-Abelló A/S (1) · Alladapt Immunotherapeutics, Inc. (1) · Allertein Therapeutics, LLC (1) · Alton Melton (1) · Baylor College of Medicine (1) · Beth Israel Deaconess Medical Center (1) · Boston Children's Hospital (1) · Cambridge University Hospitals NHS Foundation Trust (1) · IgGenix Australia Pty Ltd (1) · Insignis Therapeutics, Inc. (1) · Intrommune Therapeutics (1)
United States (24) · Canada (2) · Australia (1) · Denmark (1) · United Kingdom (1)
Edwin Kim, MD (3) · Robert Wood, MD (3) · Wesley Burks, MD (3) · Scott Sicherer, MD (2) · Andrew MacGinnitie, MD, PhD (1) · Andrew T Clark, MB BD MD (1) · Carla M Davis, MD (1) · Carsten Bindslev-Jensen, Prof. Dr. (1) · Christina E Ciaccio, MD (1) · David Fleischer, MD (1) · Hugh A. Sampson, MD (1) · Jaclyn Bjelac, MD (1) · Jacqueline Pongracic, MD (1) · Jonathan Spergel, MD, PhD (1) · Kari Nadeau, MD, PhD (1)
PMID 32414772, PMID 38010254, PMID 19226304, PMID 21414048, PMID 23265698, PMID 25528358, PMID 25656999, PMID 26920463, PMID 29700872, PMID 31676085, PMID 33463542, PMID 34755130, PMID 34813505, PMID 39842774
R01AT004435 (1), U19AI095261 (1)